Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Research article published in The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2019)
Abstract
INTRODUCTION: Postpartum hemorrhage (PPH) is the leading cause of maternal mortality worldwide with a prevalence rate of approximately 6%. Although most cases of PPH have no identifiable risk factors, the incidence of PPH has been associated to the thromboprophylaxis in pregnancy with low molecular weight heparin (LMWH). Thus, the aim of the study is to evaluate the risk of PPH in cases of pregnant women exposed to LMWH. MATERIALS AND METHODS: Electronic research was performed in OVID, Scopus, ClinicalTrials.gov, MEDLINE, the PROSPERO International Prospective Register of Systematic Reviews, EMBASE, and the Cochrane Central Register of Controlled Trials through April 2016. We included randomized controlled trials, cohort and case-control studies of women who underwent thromboprophylaxis with LMWH during pregnancy compared to a control group (either placebo or no treatment). The primary outcome was the incidence of PPH. The summary measures were reported as relative risk (RR) or as mean differences (MD) with 95% confidence interval (CI). RESULTS: Eight studies including 22,162 women were analyzed. Of the 22,162 women, 1320 (6%) were administered LMWH, 20,842 (94%) women formed the nonexposed group (control group). Women treated with LMWH had a higher risk of PPH (RR 1.45, 95%CI 1.02-2.05) compared to controls; there was no difference in mean of blood loss at delivery (MD -32.90, 95%CI 68.72-2.93) and in risk of blood transfusion at delivery (RR 1.24, 95%CI 0.62-2.51), respectively. CONCLUSIONS: Women who receive LMWH during pregnancy have a significantly higher risk of developing PPH. Women who receive LMWH during pregnancy have neither significantly higher mean blood loss at delivery nor higher risk of blood transfusion.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Por qué esto importa para la hirudoterapia
Esta revisión sistemática y metaanálisis de ocho estudios y 22.162 mujeres encontró que la tromboprofilaxis con heparin durante el embarazo estuvo asociada con un riesgo significativamente mayor de hemorragia posparto (RR 1,45, IC del 95% 1,02-2,05), aunque sin una diferencia significativa en la pérdida media de sangre o en el riesgo de transfusión. Su relevancia para la hirudoterapia es indirecta, ilustrando los compromisos de sangrado inherentes a los anticoagulantes sistémicos como heparin, en contraste con el sangrado local, autolimitado de la aplicación de sanguijuelas. La advertencia es sustancial: este metaanálisis se refiere a LMWH sistémica en pacientes obstétricas y no tiene conexión con sanguijuelas medicinales o el secretoma de la sanguijuela, por lo que ofrece solo un contexto de anticoagulación general y sin apoyo para la terapia con sanguijuelas.
Citación
Low molecular weight heparin use during pregnancy and risk of postpartum hemorrhage: a systematic review and meta-analysis.
Sirico et al. · The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2019
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026